九芝堂拟3.1亿元控股吉象隆

Core Viewpoint - The company Jiuzhitang (000989) plans to acquire a controlling stake in Harbin Jixianglong Biotechnology Co., Ltd. for a total of 2.1 billion yuan, which will enhance its product offerings and improve its financial performance [1] Group 1: Transaction Details - Jiuzhitang will acquire 35% of Jixianglong's existing shares from current shareholders for 2.1 million yuan and will subscribe to an additional 16.67% of new registered capital for 1 billion yuan [1] - After the completion of the transaction, Jiuzhitang will hold a total of 51.67% of Jixianglong, which will become a subsidiary included in Jiuzhitang's consolidated financial statements [1] Group 2: Company Profile - Jixianglong is a national high-tech enterprise specializing in the research, production, and technical services of peptide generic drugs and innovative drug formulations [1] Group 3: Strategic Implications - The acquisition is expected to enrich Jiuzhitang's product categories and improve its industry chain layout, thereby expanding its business scale and enhancing profitability [1] - The consolidation of Jixianglong's financials is anticipated to increase Jiuzhitang's revenue and profit levels, improving its risk resistance and sustainable profitability [1]